BioNTech stock price target raised to $120 from $110 at TD Cowen on Comirnaty sales

BioNTech reported mixed second-quarter results, with Comirnaty sales of €153 million and total revenue of €260.8 million significantly exceeding analyst estimates, though the company posted a net loss of €386.6 million (-€1.60/share), slightly wider than anticipated. Despite the net loss, analysts like TD Cowen and Clear Street raised their price targets to $120 and $185 respectively, driven by the strong revenue performance, a collaboration with Bristol Myers Squibb, and upcoming pipeline data readouts, as BioNTech reaffirmed its fiscal year 2025 guidance.

Analysis

BioNTech's second-quarter 2025 results present a mixed but forward-looking picture, driving positive analyst sentiment despite underlying losses. The company reported a significant revenue beat, with total revenues of €260.8 million more than doubling year-over-year and substantially exceeding the €137.9 million consensus estimate. This outperformance was primarily fueled by Comirnaty sales of €153 million, which nearly doubled the expected €85 million. However, this top-line strength did not translate to profitability, as the company posted a net loss of €386.6 million, or -€1.60 per share, which was wider than the anticipated loss of -€1.41 per share. Despite the loss, the market is focusing on future growth catalysts, evidenced by price target upgrades from TD Cowen to $120 and Clear Street to $185. These revised targets are underpinned by the revenue outperformance, a strategic collaboration with Bristol Myers Squibb, and a series of upcoming data readouts for its oncology pipeline, including BNT327, BNT111, and BNT122, expected in late 2025 and early 2026. The company’s reaffirmed fiscal year 2025 guidance and its robust balance sheet, holding more cash than debt, provide further support for the optimistic outlook.

Key Decisions for Investors

• Investors should evaluate BioNTech based on its forward-looking pipeline and strategic collaborations, as the current positive market sentiment is clearly prioritizing future growth potential over the present net loss.
• Monitor the upcoming clinical data readouts for BNT327, BNT111, and BNT122 in late 2025 and early 2026, as these events represent significant near-term catalysts that could heavily influence the stock's valuation.
• While analyst ratings are bullish, the disconnect between strong revenue growth and widening losses warrants caution; consider the company's cash burn rate against its strong cash position when assessing risk.